Cohance Lifesciences Limited has informed the Exchange about Transcript
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cohance Lifesciences reported its first full quarter under the unified Cohance brand, with overall revenue growth of 13% year-on-year in Q1 FY'26, led by the Specialty Chemicals and API segments. Pharma CDMO showed just 1% YoY growth due to temporary inventory de-stocking in two large commercial molecules, but underlying growth exceeded 30% adjusted for this impact. Niche technology revenue share rose from mid-teens in FY'25 to above 20% in Q1, with management guiding it to reach mid-20s by FY'26 end. The company committed $10 million for ADC bioconjugation capacity expansion at NJ Bio's Princeton facility and INR 230 million for a cGMP oligonucleotide building block facility at Nacharam, expected operational by end of CY'25. Management reiterated its long-term target of $1 billion (INR 85 billion) revenue by 2030 and mid-30s EBITDA margins, supported by free cash flow of INR 2.3 billion and a cash balance of INR 4.4 billion. Key leadership changes include appointing Yann D'Herve as CEO of the CDMO business and forming an External Advisory Board of 5 industry veterans.
Investors should note that the headline 1% CDMO growth masks healthy underlying momentum of 30%+, with de-stocking expected to be a temporary year-long phenomenon. The reaffirmed 2030 targets and rising niche technology mix (20%+ of revenue) signal a margin expansion story over the medium term, though near-term margins remain pressured by capacity investments and integration costs.